Sign In
Samples
/
Imfinzi
Oncology
Imfinzi
durvalumab
Manufacturer
AstraZeneca
Indication
PD-L1 inhibitor for NSCLC, SCLC, biliary tract cancer
Restrictions:
Oncology specialty required
Check My Eligibility
How It Works
1
Enter your NPI number and email address
2
We check your eligibility with AstraZeneca
3
Order samples instantly or request access
Free for healthcare providers
350K+ providers use PrescriberPoint
More from AstraZeneca
View all
Farxiga
dapagliflozin
Diabetes
Tagrisso
osimertinib
Oncology
Lynparza
olaparib
Oncology
Brilinta
ticagrelor
Cardiovascular
Fasenra
benralizumab
Respiratory
Breztri Aerosphere
budesonide/glycopyrrolate/formoterol
Respiratory
More Oncology Samples
View all
Keytruda
pembrolizumab
Merck
Tecentriq
atezolizumab
Genentech (Roche)
Darzalex
daratumumab
Janssen (J&J)
Herceptin
trastuzumab
Genentech (Roche)
Ibrance
palbociclib
Pfizer
Avastin
bevacizumab
Genentech (Roche)
Popular Samples
Browse all
Mounjaro
tirzepatide
Eli Lilly
Diabetes
Ozempic
semaglutide injection
Novo Nordisk
Diabetes
Zepbound
tirzepatide
Eli Lilly
Obesity
Eliquis
apixaban
Pfizer
Cardiovascular
Dupixent
dupilumab
Sanofi
Immunology
Jardiance
empagliflozin
Eli Lilly
Diabetes
105+
Products Available
50+
Manufacturers
20+
Therapeutic Areas
Imfinzi (durvalumab) Drug Samples | PrescriberPoint | PrescriberPoint